By SOLA OGUNDIPE
Findings of the first clinical trial to evaluate combination therapy for treatment of gonorrhoea, also called the “gentleman’s disease” are to be presented at the 20th Meeting of the International Society for Sexually Transmitted Diseases Research, ISSTDR, in Vienna, Austria.
Two new antibiotic treatments using injectable gentamicin in combination with oral azithromycin and oral gemifloxacin in combination with oral azithromycin, uccessfully treated gonorrhea infections in a clinical trial conducted by the Centers for Disease Control and Prevention, CDC, and the National Institutes of Health, NIH in the face of growing antibiotic resistance.
Researchers found 100 percent effectiveness of the injectable gentamicin/oral azithromycin combination in curing genital gonorrhea infections, and 99.5 percent effectiveness of the oral gemifloxacin/oral azithromycin combination. Both combinations cured 100 percent of infections of the throat and rectum.
Although this does not change current gonorrhoea treatment guidelines. CDC still recommends only injectable ceftriaxone, in combination with either azithromycin or doxycycline. Gonorrhea is one of the most common STIs thatcan cause serious health problems, particularly for women, while increasing a person’s risk of contracting and transmitting HIV.